The effect of high-flux hemodialysis on renal anemia

Journal of Nephrology

Volumn 17, Issue 5, 2004, Pages 701-706

  Ayli, Deniz ^a   Ayli, Meltem ^a   Azak, Alper ^a   Yüksel, Cüneyt ^a   Koşmaz, Gözde Petek ^a   Atilgan, Gökhan ^a   Dede, Fatih ^a   Abayli, Ekrem ^a   Çamlibel, Mine ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Ya am Dialysis Center   (Turkey)

Author keywords

Anemia; Beta2 microglobulin; End stage renal disease; Erythropoietin; Hemodialysis; High flux dialysis

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CYANOCOBALAMIN; FERRITIN; FOLIC ACID; HEMOGLOBIN; IRON; PARATHYROID HORMONE; PHOSPHOROUS ACID; POLYSULFONE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; UREA;

ACUTE GLOMERULONEPHRITIS; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; ARTIFICIAL KIDNEY; BETA 2 MICROGLOBULIN URINE LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; FEMALE; FERRITIN BLOOD LEVEL; FOLIC ACID BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; INTERMETHOD COMPARISON; INTERSTITIAL NEPHRITIS; IRON BLOOD LEVEL; KIDNEY DISEASE; MALE; METHODOLOGY; NEPHROSCLEROSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRANSFERRIN BLOOD LEVEL; UREA BLOOD LEVEL; URINE VOLUME; ARTIFICIAL MEMBRANE; BLOOD; CHRONIC KIDNEY FAILURE; DRUG RESISTANCE; INSTRUMENTATION; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; DRUG RESISTANCE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; RENAL DIALYSIS;

EID: 16644362600     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. US Renal Data System. USRDS 1997 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, April 1999.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32 (suppl 3): S112-9.
3. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61.
4. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-90.
5. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and erythropoetin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 1998; 13: 1642-4.
6. Eschbach JW. The anemia of chronic renal failure. Pathophysiology and the effect of recombinant erythropoietin. Kidney Int 1989; 39: 134-48.
7. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J. Regression of left ventricular hypertrophy after partial correction of anemia with erytropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35: 280-7.
8. Sugarman JR, Frederick PR, Frankenfield DL, Owen WF Jr, Mc-Clellan WM. Developing clinical performance measures based on the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: process, outcomes, and implications. Am J Kidney Dis 2003; 42: 806-12.
9. European Best Practice Guidelines for management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 (suppl 9): S1-50.
10. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996; 334: 420-5.
11. Ifudu O, Uribarri J, Rajwani I, Vlacich V, Reydel K, Delosreyes G, Friedman EA. Adequacy of dialysis and differences in hematocrit among dialysis facilities. Am J Kidney Dis 2000; 36: 1166-74.
12. Young EW, Woods JW, Segieda GE, Held PJ, Port FK, Bloembergen WE. Predictors of target hematocrit among erythropoietin-treated hemodialysis patients. J Am Soc Nephrol 1997; 8: 259A.
13. McClellan WM, Frankenfield DL, Johnson CA, Owen WF, Rocco MV, Wish JB, ESRD Core Indicators Working Group. Hematocrit and erythropoietin dose are associated with dose of dialysis among adult hemodialysis patients: results from the 1998 ESRD Core Indicators Project. J Am Soc Nephrol 2000; 11: 287A.
14. Movilli E, Cancarini GC, Zani R, Camerini C, Sandrini M, Maiorca R. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 2001; 16: 111-4.
15. Katzarski KS, Charra B, Luik AJ, Nisell J, Divino Filho JC, Leypoldt JK, Leunissen KM, Laurent G, Bergström J. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 1999; 14: 369-75.
16. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-13.
17. Locatelli F, Del Vecchio L, Andrulli S. Dialysis: its role in optimizing recombinant erythropoietin treatment. Nephrol Dial Transplant 2001; 16 (supp 7): S29-35.
18. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 1984; 25: 437-44.
19. Niwa T, Yazawa T, Kodama T. Efficient removal ol albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis in continuous ambulatory peritoneal dialysis. Nephron 1990; 56: 241-5.
20. Kobayashi H, Ono T, Yamamoto N. Removal of high molecular weight substances with large pore size membrane (BK-F). Kidney Dial 1993; 34 (suppl): S154-7.
21. Locatelli F, Andrulli S, Pecchini F, Pedrini L, Agliata S, Lucchi L, Farina M, La Milia V, Grassi C, Borghi M, Redaelli B, Conte F, Ratto G, Cabiddu G, Grossi C, Modenese R. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1399-409.
22. Locatelli F, Mastrangelo F, Redaelli B, Ronco C, Marcelli D, La Greca G, Orlandini G. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996; 50: 1293-302.
23. Opatrny K Jr, Reischig T, Vienken J, Eiselt J, Vit L, Opatrna S, Sefrna F, Racek J, Brown GS. Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis. Artif Organs 2002; 26: 181-8.
24. Wizemann V, Lotz C, Techert F, Uthoff S. On-line haemodiafiltration versus low-flux haemodialysis. A prospective randomized study. Nephrol Dial Transplant 2000; 15 (suppl 1): S43-8.
25. Richardson D, Lindley EJ, Bartlett C, Will EJ. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response. Am J Kidney Dis 2003; 42: 551-60.
26. Maduell F, del Pozo C, Garcia H, Sanchez L, Hdez-Jaras J, Alberto MD, Calvo C, Torregrosa I, Navarro V. Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 1999; 14: 1202-7.
27. Eiselt J, Racek J, Opatrny K Jr. The effect of hemodialysis and acetate-free biofiltration on anemia. Int J Artif Organs 2000; 23: 173-80.
28. Bonforte G, Grillo P, Zerbi S, Surian M. Improvement of anemia in hemodialysis patients treated by hemodiafiltration with high-volume on-line-prepared substitution fluid. Blood Purif 2002; 20: 357-63.
29. Lin CL, Huang CC, Yu CC, Wu CH, Chang CT, Hsu HH, Hsu PY, Yang CW. Improved iron utilization and reduced erythropoietin resistance by on-line hemodiafiltration. Blood Purif 2002; 20: 349-56.
30. Schrander vd Meer AM, ter Wee PM, Donker AJ, van Dorp WT. Dialysis efficacy during acetate-free biofiltration. Nelphrol Dial Transplant 1998; 13: 370-4.
31. Basile C, Giordano R, Montanaro A, De Maio P, De Padova F, Marangi AL, Semeraro A. Effect of acetate-free biofiltration on the anaemia of haemodialysis patients: a prospective cross-over study. Nephrol Dial Transplant 2001; 16: 1914-9.